Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial
Highlight
– Abelacimab, a novel factor XI inhibitor, significantly reduces major and clinically relevant nonmajor bleeding compared to rivaroxaban in atrial fibrillation (AF) patients.
– This bleeding risk reduction is consistent regardless of concurrent use of antiplatelet therapy (APT).
– Patients on concomitant APT experience greater absolute risk reductions with abelacimab.
– Factor XI inhibition offers a promising, safer anticoagulant option for AF patients requiring antiplatelet therapy.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.